Soleno Therapeutics Inc Stock Price, News & Analysis

Soleno Therapeutics, a clinical-stage biopharmaceutical firm, announced CEO Anish Bhatnagar will present a corporate overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting May 24 at 7 AM ET on the company’s website. Soleno focuses on developing therapeutics for rare diseases, with its lead candidate, DCCR, a treatment for Prader-Willi syndrome, currently in Phase 3 clinical trials.

Soleno Therapeutics (NASDAQ: SLNO) provided a corporate update and financial results for Q1 2022, reporting a net loss of approximately $5.7 million, down from $9.0 million in Q1 2021. The company is focused on obtaining FDA alignment for a New Drug Application for DCCR, its lead candidate for Prader-Willi Syndrome (PWS). Soleno closed a $15 million public offering, enhancing its financial position with $29 million in cash as of March 31, 2022. R&D expenses decreased to $4 million from $7.2 million, while general and administrative costs also fell.

Soleno Therapeutics (NASDAQ: SLNO) announced effective results from its DESTINY PWS study on diazoxide choline extended-release (DCCR) tablets for Prader-Willi Syndrome (PWS). Key findings presented at two 2022 pediatric meetings show significant reductions in hyperphagia and behavioral issues among patients treated with DCCR over 52 weeks. Statistical improvements were noted in HQ-CT total scores and various behavioral domains (p<0.001). CEO Anish Bhatnagar highlighted confidence in DCCR as a potential treatment, with data submitted to the FDA for a New Drug Application.

Soleno Therapeutics (NASDAQ: SLNO) announced the closing of a public offering, selling 40 million shares at $0.25 each, generating approximately $14.8 million in gross proceeds. Additionally, investors could purchase pre-funded warrants for $0.24 each, allowing for the purchase of 20 million shares. Proceeds will primarily fund research and development for DCCR tablets, aimed at treating Prader-Willi Syndrome (PWS). The offering was registered with the SEC and co-managed by Oppenheimer & Co., Inc. and Laidlaw & Company.

Soleno Therapeutics (NASDAQ: SLNO) announced its fourth quarter and full-year financial results for 2021. The company received FDA meeting minutes regarding data adequacy for a potential NDA submission for DCCR in treating Prader-Willi syndrome (PWS). Soleno plans to initiate a new study with currently enrolled participants. The company closed a $15 million public offering on March 31, 2022. Financially, R&D expenses were $3.8 million for Q4 2021, down from $5.6 million year-over-year, while the net loss for the year increased to $30.9 million from $24.6 million. As of December 31, 2021, cash reserves decreased to $21.3 million.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) has priced a public offering of 40 million shares at $0.25 each, with 20 million pre-funded warrants at $0.24, totaling gross proceeds of approximately $14.8 million. The offering includes accompanying warrants exercisable at $0.30 per share. Proceeds will fund research on DCCR tablets for Prader-Willi Syndrome and cover general corporate purposes. The offering is set to close around March 31, 2022, subject to customary conditions. Oppenheimer & Co. Inc. is the sole book-running manager.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) announced its intention to offer and sell shares of common stock and pre-funded warrants in an underwritten public offering. Each share or pre-funded warrant will be sold with an exercisable common warrant. The offering's completion and terms are subject to market conditions. Proceeds will primarily fund research and development of the DCCR tablets for Prader-Willi Syndrome, along with general corporate purposes. Oppenheimer & Co. Inc. is the sole book-running manager for this offering.

Soleno Therapeutics (NASDAQ: SLNO) announced that Running for Research - Prader-Willi Syndrome will fund a clinical study of Diazoxide Choline Extended-Release (DCCR) for early-phase Prader-Willi Syndrome (PWS) patients. The multi-center trial will involve 40 subjects at four U.S. institutions, aiming to assess DCCR's effectiveness in preventing hyperphagia progression. Initial data from ongoing Phase 3 trials indicate potential benefits of DCCR. Running for Research exceeded their funding goals significantly, reflecting strong community support for the study.

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company, announced its CEO Anish Bhatnagar will present a corporate overview at the BIO CEO & Investor Conference on February 15, 2022, at 2:15 PM Eastern Time. The company focuses on developing novel therapeutics for rare diseases. Its lead candidate, DCCR extended-release tablets, is in Phase 3 clinical development for treating Prader-Willi Syndrome (PWS). For more information, visit www.soleno.life.